Evidence map›Paper›PMID 36626373›Full record

ArticlePloS one2023

Using canavanine resistance to measure mutation rates in Schizosaccharomyces pombe.

Chen-Chun Pai, Ellen Heitzer, Sibyl Bertrand, Sophia Toumazou, Timothy C Humphrey, Stephen E Kearsey

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Secure biosystems design inApplied and environmental microbiology · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Chen-Chun PaiDepartment of Oncology, CRUK-MRC Oxford Institute for Radiation Oncology, University of Oxford, ORCRB, Oxford, United Kingdom.ORCID 0000-0002-0368-7843
Ellen HeitzerInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Sibyl BertrandZRAB, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-8258-2099
Sophia ToumazouZRAB, University of Oxford, Oxford, United Kingdom.
Timothy C HumphreyDepartment of Oncology, CRUK-MRC Oxford Institute for Radiation Oncology, University of Oxford, ORCRB, Oxford, United Kingdom.
Stephen E KearseyZRAB, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-3339-2667
University of Oxford · GBMedical University of Graz · AT

Funding

Medical Research Council MR/L016591/1Medical Research Council MR/X006778/1Medical Research Council MR/X006778/2
6 · The paper itself

Abstract

We constructed a panel of S. pombe strains expressing DNA polymerase ε variants associated with cancer, specifically POLES297F, POLEV411L, POLEL424V, POLES459F, and used these to compare mutation rates determined by canavanine resistance with other selective methods. Canavanine-resistance mutation rates are broadly similar to those seen with reversion of the ade-485 mutation to adenine prototrophy, but lower than 5-fluoroorotic acid (FOA)-resistance rates (inactivation of ura4+ or ura5+ genes). Inactivation of several genes has been associated with canavanine resistance in S. pombe but surprisingly whole genome sequencing showed that 8/8 spontaneous canavanine-resistant mutants have an R175C mutation in the any1/arn1 gene. This gene encodes an α-arrestin-like protein involved in mediating Pub1 ubiquitylation of target proteins, and the phenotypic resistance to canavanine by this single mutation is similar to that shown by the original "can1-1" strain, which also has the any1R175C mutation. Some of the spontaneous mutants have additional mutations in arginine transporters, suggesting that this may marginally increase resistance to canavanine. The any1R175C strain showed internalisation of the Cat1 arginine transporter as previously reported, explaining the canavanine-resistance phenotype.

Indexed as

SchizosaccharomycesSchizosaccharomyces pombe ProteinsArginineArrestinsCanavanineMutationMutation RateAny1 protein, S pombeArginineArrestinsCanavanineSchizosaccharomyces pombe Proteins

Identifiers

PMID36626373
PMCPMC9831302
OpenAlexW4314935533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.